New Clinical Trial and New Medical Report for Kidney Cancer (RCC)
The clinical trial below was posted (on clinicaltrials.gov) a few days ago. The medical report was published on PreMedlaine, also a few days ago
We offer treatment search services for the latest developments in treatment of any illness including regular weekly treatment updates. Learn more about or treatment search services.
New Clinical Trial for Kidney Cancer (RCC)
UNISoN: anzUp Nivo Then Ipi+Nivo in Sequential Non-clear Cell. (UNISoN)
This study aims to evaluate the safety, tolerability and effectiveness of new treatments for kidney cancer called Nivolumab and Ipilimumab. The study is in two parts; in the first instance patients receive nivolumab alone. If this treatment is not effective patients may move onto the second part of the trial, where they receive nivolumab + ipilimumab. There is no placebo.
The reason to offer one treatment alone, followed by two treatments together is that it is thought that the double treatment may have more side-effects, but also may be effective in people in whom the single first treatment (nivolumab alone) has not helped.
Nivolumab and ipilimumab are experimental treatments. This means that they are not an approved treatment for non-clear cell kidney cancer in Australia.
The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab (also known as Opdivo or BMS-936558) and Ipilumumab (also known as MDX-010 or Yervoy). Nivolumab and ipilimumab are antibodies (a type of human protein) that are being tested to see if they will allow the body’s immune system to work against tumour cells. The immune system is the body’s defence against cancer, bacteria and viruses. The effectiveness of nivolumab and ipilimumab in cancer of the kidney will be assessed by measuring the size of patient tumours via CT scans.
Nivolumab and ipilimumab have been used alone or in combination in many other cancers, and are licenced for use in other cancers like advanced melanoma and bladder cancer in Australia. They have not been tested in people with non-clear cell kidney cancer.
About 85 participants with non-clear cell kidney cancer are expected to participate in this study, from Australia and New Zealand.
This research study has been initiated by Dr. Craig Gedye, is being conducted in collaboration with the Centre for Biostatistics and Clinical Trials (BaCT) and sponsored in Australia by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Pty Ltd. Bristol Myers Squibb (BMS) is supplying the study drugs and grant funding for this research.
|Renal Cell Carcinoma
Papillary Renal Cell Carcinoma Type 1
Papillary Renal Cell Carcinoma Type 2
Chromophobe Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma
Xp11 Translocation Carcinoma
|Study Design:||Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma(ANZUP1602).|
Primary Outcome Measures:
- The objective tumour response rate, as assessed by RECIST1.1 [ Time Frame: Through study completion, on average 5 years. ]
This is defined as the proportion of participants in the analysis set with a confirmed complete response (CR) or partial response (PR) divided by the number of participants in the analysis set.
Secondary Outcome Measures:
- Duration of objective tumour response, as assessed by RECIST1.1 [ Time Frame: Through study completion, on average 5 years. ]
Measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease is objectively documented.
- Progression-free survival (PFS), as assessed by RECIST1.1 [ Time Frame: Through study completion, on average 5 years. ]
For Part 1, PFS is defined as the interval from date of registration to the date of first evidence of disease progression or death, whichever occurs first. For Part 2, PFS is defined as the interval from date of progressive disease on nivolumab monotherapy until the date of first evidence of disease progression or death, whichever occurs first.
- Immune-related tumour response rate, as assessed by irRECIST. [ Time Frame: Through study completion, on average 5 years. ]
Defined as the proportion of participants in the analysis set with an immune related complete response (irCR), or immune related partial response (irPR), divided by the number of participants in the analysis set.
- Immune-related disease control rate (irDCR6), as assessed by irRECIST. [ Time Frame: At 6 months during treatment. ]
For Part 1, irDCR6 is defined as an assessment of CR or iPR or iSD according to modified irRECIST. For Part 2, irDCR6 is defined in the same way except that the extent of disease defining the baseline tumour burden is measured at the date of disease progression on nivolumab monotherapy.
- The number of patients alive at the end of the study, as assessed by date of death. [ Time Frame: Through study completion, on average 5 years. ]
Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.
- The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03. [ Time Frame: From time of patient registration, until 30 days after the last dose of treatment. ]
- The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03. [ Time Frame: From time of patient registration, until 30 days after the last dose of treatment. ]
Other Outcome Measures:
- The biomarkers of response and resistance to anti-cancer treatments, as assessed by gene expression arrays, cytokine arrays, multiplex immunohistochemistry and mass cytometry on tissue and blood samples. [ Time Frame: Through study completion, on average 5 years. ]
|Anticipated Study Start Date:||September 2017|
|Estimated Study Completion Date:||December 2022|
|Estimated Primary Completion Date:||December 2021 (Final data collection date for primary outcome measure)|
|Experimental: Nivolumab and Ipilimumab
Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.
Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months.
Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.
Storage Condition: 2 to 8°C. Protect from light and freezing.
Other Name: Opdivo
Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
Other Name: Yervoy
|Ages Eligible for Study:||18 Years and older (Adult, Senior)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed unresectable, locally advanced (defined as disease not amenable to curative surgery or radiation therapy) or metastatic nccRCC (both treatment-naïve or those treated with a VEGFR TKI or another systemic medical therapy). Non-clear cell histology including:
- Papillary renal cell carcinoma (type 1)
- Papillary renal cell carcinoma (type 2)
- Other: including chromophobe renal cell carcinoma, sarcomatoid renal cell carcinoma, Xp11 translocation (TFE3+ IHC) carcinoma, other renal carcinoma NOS
- Be ≥18 years of age on the day of signing informed consent
- At least 1 target lesion according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Adequate bone marrow function (should be performed within 14 days prior to registration and with values within the ranges specified below):
- Haemoglobin ≥ 90g/L
- Platelets ≥ 100×109/L
- Neutrophil count ≥ 1.5×109/L
- Adequate liver function (should be performed within 14 days prior to registration and with values within the ranges specified below):
- Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for participants with known Gilbert’s syndrome who can have total bilirubin < 3.0 mg/dL
- AST or ALT ≤ 3.0 x ULN (or ≤ 5.0x ULN in the presence of liver metastases)
- Adequate renal function (should be performed within 14 days prior to registration and with values within the ranges specified below):
- Creatinine ≤ 1.5x ULN OR
- Creatinine clearance (CrCl) ≥ 30mL/min (use Cockcroft-Gault Formula)
- Female participants of childbearing potential should have a negative urine or serum pregnancy within 24 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female participants of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- Male participants should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- Able to provide a formalin-fixed paraffin embedded (FFPE) tumour block, representative of the participant’s primary or metastatic disease (preferred), which must be forwarded to the Centre for Biostatistics and Clinical Trials (BaCT) within 10 working days post registration
- Willing and able to start treatment within 14 days of registration, and to comply with all study requirements, including the timing and/or nature of the required treatment and assessments
- Has provided signed, written informed consent.
- Urothelial or transitional cell carcinoma of the renal pelvis or ureter
- Predominant clear cell renal cell carcinoma. A minority of clear cell histology (<50%) is acceptable, but there must be >50% non-clear cell histology predominant.
- Participation in a study of an investigational agent within 30 days of registration.
- Prior treatment with nivolumab, ipilimumab, or with any other anti-PD-1, anti-PD-L1, Anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways (NB Participant is eligible for Part 2 of the study if they took nivolumab monotherapy in Part 1 of the study).
- Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Any condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone or equivalent dose of alternative corticosteroid) or other immunosuppressive medications within 14 days of registration. Intranasal, inhaled or topical steroids are permitted in the absence of active autoimmune disease. Participants are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
- Untreated brain or leptomeningeal metastases or current clinical or radiological progression of known brain metastases or requirement for steroid therapy for brain metastases. Participants with treated brain metastases are eligible if they have been stable and off steroids for ≥ 3 weeks.
- Prior allogeneic organ transplant, inflammatory bowel disease, pneumonitis, tuberculosis, or primary immunodeficiency
- Active infection requiring systemic therapy within 14 days before registration.
- Receipt of live attenuated vaccination within 30 days of registration.
- Life expectancy of less than 3 months.
- Prior systemic therapy, surgery or radiation therapy within 4 weeks before registration.Note: If the participant has undergone major surgery, they must have recovered adequately before registration.
- History of another active malignancy within the previous 5 years, except for locally curable cancers that have been apparently cured, such as low-grade thyroid carcinoma, prostate cancer not requiring treatment (Gleason grade ≤ 6), basal or squamous cell skin cancer, superficial bladder cancer, melanoma in situ or carcinoma in situ of the prostate, cervix, or breast. Participants who have been free of other malignancies for ≥ 5 years prior to registration are eligible for this study.
- Positive test for hepatitis B virus surface antigen (HBVsAg) or antibodies to hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
- A history of other significant infection, including HIV. HIV testing is not mandatory unless clinically indicated.
- Participants should be excluded if they have a history of allergy to study drug components, or a history of severe hypersensitivity reaction to any monoclonal antibody.
- Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol
- Female patient is pregnant or lactating.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03177239
|Contact: Craig Gedye, MBBS, FRACP||+61 2 4014 firstname.lastname@example.org|
|Contact: Ian Davis, MBBS, FRACP||+613 9094 email@example.com|
|Australia, New South Wales|
|Chris O’Brien Lifehouse||Not yet recruiting|
|Camperdown, New South Wales, Australia, 2050|
|Contact: Michelle Harrison, MBBS, FRACP Michelle.Harrison@lh.org.au|
|Contact: Jacqui Harvey, RN firstname.lastname@example.org|
|Principal Investigator: Michelle Harrison, MBBS, FRACP|
|St. George Hospital||Not yet recruiting|
|Kogarah, New South Wales, Australia, 2217|
|Contact: Carole Harris, MBBS, FRACP email@example.com|
|Contact: Mary Gozar, RN Mary.Gozar@SESIAHS.HEALTH.NSW.GOV.AU|
|Principal Investigator: Carole Harris, MBBS, FRACP|
|Calvary Mater Newcastle||Not yet recruiting|
|Newcastle, New South Wales, Australia, 2298|
|Contact: Craig Gedye, MBBS, FRACP firstname.lastname@example.org|
|Contact: Kim Adler, RN +612 40143282 email@example.com|
|Principal Investigator: Craig Gedye, MBBS, FRACP|
|Prince of Wales Hospital||Not yet recruiting|
|Randwick, New South Wales, Australia, 2031|
|Contact: Elizabeth Hovey, MBBS, FRACP Elizabeth.Hovey@health.nsw.gov.au|
|Contact: Danielle Osmond, RN Danielle.Osmond@health.nsw.gov.au|
|Principal Investigator: Elizabeth Hovey, MBBS, FRACP|
|Tamworth Hospital – North West Cancer Centre||Not yet recruiting|
|Tamworth, New South Wales, Australia, 2340|
|Contact: Mathew George, MBBS, FRACP Mathew.firstname.lastname@example.org|
|Contact: Margeret Chamen, RN email@example.com|
|Principal Investigator: Mathew George, MBBS, FRACP|
|Westmead Hospital||Not yet recruiting|
|Westmead, New South Wales, Australia, 2145|
|Contact: Howard Gurney, MBBS, FRACP firstname.lastname@example.org|
|Principal Investigator: Howard Gurney, MBBS, FRACP|
|Royal Brisbane & Women’s Hospital||Not yet recruiting|
|Brisbane, Queensland, Australia, 4000|
|Contact: Jeffrey Goh, MBBS, FRACP email@example.com|
|Contact: Annette Cubitt, RN firstname.lastname@example.org|
|Principal Investigator: Jeffrey Goh, MBBS, FRACP|
|Australia, South Australia|
|Flinders Medical Centre||Not yet recruiting|
|Adelaide, South Australia, Australia, 5000|
|Contact: Ganessan Kichenadasse, MBBS, FRACP email@example.com|
|Contact: Kelly Mead, RN Kelly.Mead@health.sa.gov.au|
|Principal Investigator: Ganessan Kichenadasse, MBBS, FRACP|
|Box Hill Hospital – Eastern Health||Not yet recruiting|
|Box Hill, Victoria, Australia, 3128|
|Contact: Ian Davis, MBBS, FRACP firstname.lastname@example.org|
|Contact: Sue Cranmer, RN email@example.com|
|Principal Investigator: Ian Davis, MBBS, FRACP|
|Austin Health||Not yet recruiting|
|Melbourne, Victoria, Australia, 3084|
|Contact: Andrew Weickhardt, MBBS, FRACP firstname.lastname@example.org|
|Contact: Joanne Hakanson, RN Joanne.HAKANSON@austin.org.au|
|Principal Investigator: Andrew Weickhardt, MBBS, FRACP|
|Responsible Party:||Australian and New Zealand Urogenital and Prostate Cancer Trials Group|
|ClinicalTrials.gov Identifier:||NCT03177239 History of Changes|
|Other Study ID Numbers:||ANZUP 1602|
|Study First Received:||June 4, 2017|
|Last Updated:||June 7, 2017|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Additional relevant MeSH terms:
|Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Physiological Effects of Drugs
ClinicalTrials.gov processed this record on June 12, 2017